Rabid demand for weight-loss drugs like Ozempic and Wegovy is altering US society and transforming the healthcare industry. Rapid Response host Bob Safian guides us through the upheaval and lessons, talking with CEO Zach Reitano of Ro, a telehealth platform that has ridden the wave to a $7 billion valuation. Reitano shares why he chose obesity-treatment as his company’s “hero product,” the impact of weight-loss drugs on industries beyond health-care, and why the potential of GLP-1s like Ozempic mirrors that of AI.Read a transcript of this episode: https://mastersofscale.comSubscribe to the Masters of Scale weekly newsletter: https://mastersofscale.com/subscribeSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.